Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1983 Sep;15(3):227–236. doi: 10.1007/BF00199170

Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture

Clonal analysis of effector cells in cytotoxic and proliferative assays

B M Vose 1,✉, W White 1
PMCID: PMC11039266  PMID: 6225511

Abstract

Lymphocytes from cancer patients were stimulated in mixed culture with autologous tumour (MLTC) or pooled allogeneic lymphocytes (MLC). Both protocols induced increased uptake of 3H-thymidine at 5 days and the appearance of lymphoblasts. Blasts were isolated on discontinuous Percoll gradients and either expanded as bulk cultures or cloned directly under limiting dilution conditions in the presence of conditioned medium containing IL-2. Results with MLTC-blast-CTC have been reported elsewhere. MLC-activated cultures lysed autologous tumour but not autologous lymphoblasts. Lysis of some allogeneic tumours, lymphoblasts from members of the inducing pool, and K562 was also apparent. MLC activated cultures did not undergo restimulation in response to autologous tumour or lymphocytes but were restimulated by leukocytes from pool members.

MLTC clones showed autologous tumour-specific cytotoxic activity or cross-reactive proliferative responses with tumours of the same site and histology. The majority of MLC clones cytotoxic for autologous tumour were also specific and did not lyse allogeneic tumour, K562, or lymphoblasts from the inducing pool. Two clones lysed autologous tumour and pool members. None of the clones tested proliferated in response to autologous tumour following MLC activation but some were responsive to pool members and one clone was restimulated by autologous monocytes. No association was found between clone phenotype and function. The implication of these data is that the effector cells with activity against autologous tumour induced in MLC arose largely by transstimulation of in vivo-activated tumour reactive lymphocytes by IL-2 release rather than expansion of NK-like effectors or sharing of antigenic specificities between tumour and allogeneic lymphocytes. Since MLC activation of cancer patients lymphocytes does not induce proliferative responses to autologous tumour it is unlikely to be a useful procedure in preparing cells for immunotherapy protocols.

Keywords: Proliferative Response, Autologous Tumour, Percoll Gradient, Dilution Condition, Allogeneic Tumour

Footnotes

Abbreviations used in this paper: PBL, peripheral blood lymphocytes; TIL, tumour infiltrating lymphocytes; MLTC, mixed lymphocyte tumour culture; IL-2, interleukin-2; MLC, mixed lymphocyte culture; LSM, lymphocyte separation medium; BSS, balanced salt solution; HuSe, human serum; PBS, phosphate-buffered saline; CTC, cultured T cells; PHA, phytohaemagglutinin; CM, cultured medium; NK, natural killer; FcR, receptor for the Fc portion of IgG

References

  • 1.Bach FH, Bach ML, Zarling JM. Pool-priming: A means of generating T lymphocytes cytotoxic to tumour or virus-infected cells. Lancet. 1978;I:20. doi: 10.1016/s0140-6736(78)90364-1. [DOI] [PubMed] [Google Scholar]
  • 2.Bach FH, Leshem B, Kuperman OJ, Bunzendahl H, Alter BJ, Zarling JM. Allosensitisation to obtain anti-tumour immunity. In: Fefer A, Goldstein A, editors. The potential role of T cells in cancer therapy. New York: Raven Press; 1982. [Google Scholar]
  • 3.Dallman MJ, Mason DW. Role of thymus-derived and thymus-independent cells in murine skin allograft rejection. Transplantation. 1982;33:221. doi: 10.1097/00007890-198203000-00002. [DOI] [PubMed] [Google Scholar]
  • 4.Fernandez-Cruz E, Woda BA, Feldman JD. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med. 1980;152:823. doi: 10.1084/jem.152.4.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Fossati G, Baksari A, Taramelli D, Sensi ML, Pellegris G, Nava M, Parmiani G (1983) Lysis of autologous human melanoma cells by in vitro allosensitised peripheral blood lymphocytes. Cancer Immunol Immunother (in press) [DOI] [PMC free article] [PubMed]
  • 6.Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine leukaemia by chemoimmunotherapy with cyclophosphamide and adaptively transferred immune syngeneic Lyt 1+2− lymphocytes. J Exp Med. 1981;154:952. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumour cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Julius MH, Simpson E, Herzenberg LA. Rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973;3:645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  • 9.Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumour by lymphocytes cultured in T cell growth factor. Cancer Res. 1981;41:4420. [PubMed] [Google Scholar]
  • 10.Loveland BE, MacKenzie IFC. Which T cells cause graft rejection? Transplantation. 1982;33:217. doi: 10.1097/00007890-198203000-00001. [DOI] [PubMed] [Google Scholar]
  • 11.Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA. Lysis of fresh human solid tumours by autologous lymphocytes activated in vitro with lectins. Cancer Res. 1982;42:913. [PubMed] [Google Scholar]
  • 12.Ortaldo JR, Timonen TT, Vose BM, Alvarez JA. Human natural killer cells as well as T cells maintained in continuous cultures with IL-2. In: Fefer A, Goldstein A, editors. The potential role of T cells in cancer therapy. New York: Raven Press; 1982. p. 191. [Google Scholar]
  • 13.Pawelec GP, Hadam MR, Ziegler A, Lohmeyer J, Rehbein A, Kumbier I, Wernet P. Long-term culture, cloning and surface markers of mixed leukocyte culture-derived human T lymphocytes with natural killer-like cytotoxicity. J Immunol. 1982;128:1892. [PubMed] [Google Scholar]
  • 14.Strausser JL, Mazumder A, Grimm EA, Lotze MT, Rosenberg SA. Lysis of human solid tumours by autologous cells sensitised in vitro to alloantigens. J Immunol. 1981;127:226. [PubMed] [Google Scholar]
  • 15.Vánky F, Klein E. Specificity of auto-tumour cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cancer. 1982;29:547. doi: 10.1002/ijc.2910290510. [DOI] [PubMed] [Google Scholar]
  • 16.Vánky F, Stjernswärd J. Lymphocyte stimulation (by autologous tumour biopsy cells) In: Herberman RB, McIntire KR, editors. Immunodiagnosis of cancer, part 2. New York: Marcel Dekker; 1979. p. 998. [Google Scholar]
  • 17.Vánky F, Klein E, Stjernswärd J, Nilsonne U, Rodriguez L, Peterffy A. Human tumour-lymphocyte interaction in vitro. II. Conditions which improve the capacity of biopsy cells to stimulate autologous lymphocytes. Cancer Immunol Immunother. 1979;5:63. [Google Scholar]
  • 18.Vánky F, Vose BM, Fopp M, Klein E. Human tumour-lymphocyte interactions in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity. J Natl Cancer Inst. 1979;62:1407. [PubMed] [Google Scholar]
  • 19.Vánky F, Gorsky T, Gorsky Y, Masucci M-G, Klein E. Lysis of tumour biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. J Exp Med. 1982;155:83–95. doi: 10.1084/jem.155.1.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Vose BM. Cytotoxicity of adherent cells associated with some human tumours and lung tissues. Cancer Immunol Immunother. 1978;5:173. [Google Scholar]
  • 21.Vose BM. Specific T-cell-mediated killing of autologous lung tumour cells. Cell Immunol. 1980;55:12. doi: 10.1016/0008-8749(80)90132-x. [DOI] [PubMed] [Google Scholar]
  • 22.Vose BM. Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: Limiting dilution analysis in peripheral blood and at the tumour site. Int J Cancer. 1982;30:135. doi: 10.1002/ijc.2910300202. [DOI] [PubMed] [Google Scholar]
  • 23.Vose BM. Separation of tumour and host cell populations from human neoplasms. In: Reid E, editor. Methodological surveys, vol II. Chichester: Ellis Harwood; 1982. p. 45. [Google Scholar]
  • 24.Vose BM, Bonnard GD. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2. Int J Cancer. 1982;29:33. doi: 10.1002/ijc.2910290107. [DOI] [PubMed] [Google Scholar]
  • 25.Vose BM, Bonnard GD. Limiting dilution analysis of the precursor cells capable of specific cytotoxic or proliferative responses to human tumour cells and their expansion with lectin-free interleukin-2. In: Serron B, editor. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical Press; 1982. p. 385. [Google Scholar]
  • 26.Vose BM, Bonnard GD (1983) Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin-2. I. The effect of lectin on the proliferative and cytotoxic activity of cultured lymphoid cells. J Immunol (in press) [PubMed]
  • 27.Vose BM, Howell A. Cultured human antitumour T cells and their potential for therapy. In: Herberman RB, editor. Clinical and basic tumour immunology. The Hague: Martinus Hyhoff; 1983. [Google Scholar]
  • 28.Vose BM, Moore M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer. 1979;24:579. doi: 10.1002/ijc.2910240510. [DOI] [PubMed] [Google Scholar]
  • 29.Vose BM, Moore M. Cultured human T-cell lines kill autologous tumour. Immunol Lett. 1981;3:237. doi: 10.1016/0165-2478(81)90081-x. [DOI] [PubMed] [Google Scholar]
  • 30.Vose BM, Vánky F, Klein E. Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans. Int J Cancer. 1977;20:512. doi: 10.1002/ijc.2910200407. [DOI] [PubMed] [Google Scholar]
  • 31.Vose BM, Vánky F, Fopp M, Klein E. In vitro generation of cytotoxicity against autologous human tumour biopsy cells. Int J Cancer. 1978;21:588. doi: 10.1002/ijc.2910210508. [DOI] [PubMed] [Google Scholar]
  • 32.Vose BM, Vánky F, Fopp M, Klein E. Restricted autologous lymphocytotoxicity in lung neoplasia. Br J Cancer. 1978;38:375. doi: 10.1038/bjc.1978.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Vose BM, Gallagher P, Moore M, Schofield PF. Specific and non-specific lymphocyte cytotoxicity in colon cancer. Br J Cancer. 1981;44:846. doi: 10.1038/bjc.1981.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Vose BM, Riccardi C, Marchmont RJ, Bonnard GD. Clonal analysis of human natural killer cells. In: Herberman RB, editor. NK cells and other natural effector cells. New York: Academic Press; 1983. p. 879. [Google Scholar]
  • 35.Zarling JM, Robins HI, Raich PC, Bach FH, Bach ML. Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells. Nature. 1978;274:269. doi: 10.1038/274269a0. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES